Clobetasol promotes remyelination in a mouse model of neuromyelitis optica.

摘要: Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system that can produce marked neurological deficit. Current NMO therapies include immunosuppressants, plasma exchange and B-cell depletion. Here, we evaluated 14 potential remyelinating drugs emerging from prior small molecule screens done to identify for repurposing in multiple sclerosis other diseases. Compounds were initially oligodendrocyte precursor cell (OPC) cerebellar slice cultures, then a mouse model produced by intracerebral injection anti-AQP4 autoantibody (AQP4-IgG) human complement characterized demyelination with minimal axonal damage. The FDA-approved drug clobetasol promoted differentiation OPC cultures remyelination mice. Intraperitoneal administration 2 mg/kg/day reduced myelin loss ~60 %, even when was administered after occurred. Clobetasol increased number mature oligodendrocytes within lesions without significantly altering initial astrocyte damage or inflammation. These results provide proof-of-concept utility approach treatment NMO.